Logo

TAK

Takeda Pharmaceutical Company Limited

TAK

Takeda Pharmaceutical Company Limited • NYSE
$14.42 ▼ -0.69% (-0.10)
Market Cap $45.47 B
52w High $15.69
52w Low $12.80
Dividend Yield 0.60%
P/E 206
Volume 2.00M
Outstanding Shares 3.15B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $1.113T ▲ $663.74B ▲ $-11.802B ▼ -1.061% ▼ $-3.74 ▼ $316.467B ▼
Q1-2025 $1.107T ▲ $537.444B ▼ $124.243B ▲ 11.227% ▲ $39.7 ▲ $439.424B ▲
Q4-2024 $1.053T ▼ $746.2B ▲ $-103.2B ▼ -9.797% ▼ $-32.62 ▼ $181.269B ▼
Q3-2024 $1.144T ▼ $660.308B ▲ $23.789B ▼ 2.079% ▼ $7.51 ▼ $193.007B ▼
Q2-2024 $1.176T $597.48B $92.046B 7.827% $29.07 $380.278B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $739.678B ▲ $14.47T ▲ $7.339T ▲ $7.131T ▲
Q1-2025 $419.175B ▲ $14.005T ▼ $7.138T ▼ $6.865T ▼
Q4-2024 $405.589B ▼ $14.248T ▼ $7.312T ▼ $6.935T ▼
Q3-2024 $526.747B ▼ $15.107T ▲ $7.688T ▲ $7.418T ▲
Q2-2024 $906.215B $14.573T $7.651T $6.921T

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-11.729B ▼ $378.228B ▲ $-48.133B ▼ $-11.981B ▲ $331.478B ▲ $325.403B ▲
Q1-2025 $124.279B ▲ $215.423B ▼ $-33.193B ▼ $-214.9B ▲ $-35.105B ▲ $140.355B ▼
Q4-2024 $-103.2B ▼ $222.159B ▼ $-19.681B ▲ $-301.792B ▲ $-109.013B ▲ $173.366B ▼
Q3-2024 $23.789B ▼ $383.756B ▲ $-115.555B ▼ $-655.969B ▼ $-364.889B ▼ $338.668B ▲
Q2-2024 $92.046B $280.963B $-75.131B $-110.045B $54.003B $231.49B

Five-Year Company Overview

Income Statement

Income Statement Revenue and gross profit have been climbing steadily over the last five years, showing that the core business is expanding and pricing/mix remain supportive. Operating profit and EBITDA are generally healthy, but have been uneven year to year, hinting at restructuring costs, product mix shifts, or one‑off items. Net income and earnings per share are much more volatile and on a downward trend versus earlier years, which suggests that below‑the‑line items, integration costs, interest, or impairments are weighing on headline profitability. Overall, the business engine looks solid, but reported earnings are choppier than the revenue story would suggest.

Balance Sheet

Balance Sheet The balance sheet is sizeable with a strong asset base built up over time, and shareholders’ equity has been gradually increasing, which is a positive sign for long‑term financial strength. Debt remains high in absolute terms and has not declined meaningfully, so leverage continues to be an important consideration and likely reflects past acquisitions and ongoing investment needs. Cash on hand has come down from earlier years, which reduces liquidity cushion but is partly offset by solid operating cash generation. In short, Takeda looks capital‑intensive but broadly stable, with leverage that needs to be carefully managed.

Cash Flow

Cash Flow Operating cash flow is consistently strong, demonstrating that the underlying business converts a good portion of its sales into cash. Free cash flow is positive across the period but quite volatile, swinging higher or lower depending mainly on investment spending and working‑capital movements. Capital expenditure jumped in some years and then eased back more recently, which can signal a peak in a major investment cycle followed by a period of harvesting those investments. Overall, the cash profile supports ongoing operations and R&D, but the variability means timing of large projects and portfolio moves matters a lot.

Competitive Edge

Competitive Edge Takeda holds a strong global position in specialized areas such as gastroenterology, rare diseases, hematology, and selected oncology niches, which gives it focused expertise and deep relationships with specialists and patient communities. The Shire acquisition significantly broadened its rare‑disease and plasma‑derived therapies platform, reinforcing scale and breadth versus many peers. Its worldwide commercial network and presence in major markets help it launch and support new drugs more effectively than smaller competitors. The main competitive risks are intense pressure in key franchises, patent expiries over time, and the need to continuously refresh the portfolio to defend this position.

Innovation and R&D

Innovation and R&D R&D is tightly focused on a few high‑value therapeutic areas, complemented by heavy use of data, digital tools, and artificial intelligence to speed up discovery and development. Takeda relies on both internal research and extensive partnerships with biotech firms and academic groups, which broadens its access to new ideas and technologies. The company has a visible late‑stage pipeline with several potential blockbuster candidates in sleep disorders, autoimmune disease, and blood‑related conditions, plus follow‑on programs into the next decade. The opportunity is substantial, but execution risk is high: clinical outcomes, regulatory approvals, and competitive launches will determine how much of this pipeline actually replaces revenues from aging blockbuster products.

Summary

Takeda shows a solid growth story on the top line, supported by strong cash generation and a focused strategy in specialized disease areas, but its reported earnings are more volatile and less flattering than its revenue trajectory. The balance sheet is anchored by a large asset base and growing equity, yet it carries meaningful debt and a thinner cash cushion than in the past, so disciplined capital allocation remains important. Competitively, Takeda benefits from specialization, global reach, and strong franchises, while its R&D engine and digital capabilities provide a credible path to future products. The key watchpoints are successful delivery of its late‑stage pipeline, management of patent cliffs and pricing pressure, and careful handling of leverage and investment cycles to turn scientific progress into durable, high‑quality earnings.

NEWS

November 19, 2025 · 6:30 AM UTC

Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery

Read more

November 7, 2025 · 11:00 AM UTC

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Read more

November 3, 2025 · 7:00 AM UTC

New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Read more

October 30, 2025 · 3:04 AM UTC

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment.

Read more

October 21, 2025 · 8:25 PM UTC

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

Read more